Fiche publication
Date publication
août 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr YUSUPOV Marat
,
Dr YUSUPOVA Gulnara
Tous les auteurs :
Pellegrino S, Terrosu S, Yusupova G, Yusupov M
Lien Pubmed
Résumé
Protein biosynthesis is a vital process for all kingdoms of life. The ribosome is the massive ribonucleoprotein machinery that reads the genetic code, in the form of messenger RNA (mRNA), to produce proteins. The mechanism of translation is tightly regulated to ensure that cell growth is well sustained. Because of the central role fulfilled by the ribosome, it is not surprising that halting its function can be detrimental and incompatible with life. In bacteria, the ribosome is a major target of inhibitors, as demonstrated by the high number of small molecules identified to bind to it. In eukaryotes, the design of ribosome inhibitors may be used as a therapy to treat cancer cells, which exhibit higher proliferation rates compared to healthy ones. Exciting experimental achievements gathered during the last few years confirmed that the ribosome indeed represents a relevant platform for the development of anticancer drugs. We provide herein an overview of the latest structural data that helped to unveil the molecular bases of inhibition of the eukaryotic ribosome triggered by small molecules.
Mots clés
X-ray crystallography, anticancer drugs, cryo-EM, drug development, protein synthesis inhibition, ribosome
Référence
Cancers (Basel). 2021 Aug 31;13(17):
